

# 1 Missed opportunities of flu vaccination in Italian 2 target categories: insights from the online EPICOVID 3 19 survey

4 Andrea Giacomelli\*<sup>1</sup>, Massimo Galli\*<sup>1</sup>, Stefania Maggi<sup>2</sup>, Gabriele Pagani<sup>1</sup>, Raffaele Antonelli  
5 Incalzi<sup>3</sup>, Claudio Pedone<sup>3</sup>, Mauro di Bari<sup>4</sup>, Marianna Noale<sup>2</sup>, Caterina Trevisan<sup>2,5</sup>, Fabrizio  
6 Bianchi<sup>6</sup>, Marcello Tavio<sup>7</sup>, Massimo Andreoni<sup>8</sup>, Claudio Mastroianni<sup>9</sup>, Aleksandra Sojic<sup>10</sup>,  
7 Federica Prinelli<sup>10</sup> and Fulvio Adorni<sup>10</sup> on Behalf of EPICOVID19 Working Group.

8 <sup>1</sup>Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di  
9 Milano, ASST Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy;  
10 [andrea.giacomelli@unimi.it](mailto:andrea.giacomelli@unimi.it); [massimo.galli@unimi.it](mailto:massimo.galli@unimi.it); [gabriele.pagani@unimi.it](mailto:gabriele.pagani@unimi.it)

11 <sup>2</sup>National Research Council, Institute of Neuroscience, Aging branch, Via Vincenzo Maria Gallucci  
12 16, 35128 Padova; [stefania.maggi@in.cnr.it](mailto:stefania.maggi@in.cnr.it); [caterina.trevisan.5@studenti.unipd.it](mailto:caterina.trevisan.5@studenti.unipd.it);  
13 [marianna.noale@in.cnr.it](mailto:marianna.noale@in.cnr.it)

14 <sup>3</sup>Unit of Geriatrics, Department of Medicine, Biomedical Campus of Rome, via Alvaro del Portillo,  
15 21, 00128 Rome, Italy; [r.antonelli@unicampus.it](mailto:r.antonelli@unicampus.it) ; [claudio.pedone@gmail.com](mailto:claudio.pedone@gmail.com)

16 <sup>4</sup>Geriatric Intensive Care Medicine, University of Florence and Azienda Ospedaliero-Universitaria  
17 Careggi, Viale Peraccini 18, 50139 Florence, Italy; [mauro.dibari@unifi.it](mailto:mauro.dibari@unifi.it)

18 <sup>5</sup>Geriatric Unit, Department of Medicine (DIMED), University of Padova, Via Giustiniani 2, 35128  
19 Padova, Italy; [caterina.trevisan.5@studenti.unipd.it](mailto:caterina.trevisan.5@studenti.unipd.it)

20 <sup>6</sup> National Research Council, Institute of Clinical Physiology, Via G. Moruzzi 1, 56124 Pisa (PI),  
21 Italy; [fabrieipi@ifc.cnr.it](mailto:fabrieipi@ifc.cnr.it)

22 <sup>7</sup>Division of Infectious Diseases, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona,  
23 Italy; [marcello.tavio@ospedaliriuniti.marche.it](mailto:marcello.tavio@ospedaliriuniti.marche.it)

24 <sup>8</sup>Infectious Diseases Clinic, Department of System Medicine, Tor Vergata University of Rome,  
25 00133 Rome, Italy; [andreoni@uniroma2.it](mailto:andreoni@uniroma2.it)

26 <sup>9</sup>Public Health and Infectious Disease Department, "Sapienza" University, Rome, Italy;  
27 [claudio.mastroianni@uniroma1.it](mailto:claudio.mastroianni@uniroma1.it)

28 <sup>10</sup>National Research Council, Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090  
29 Segrate (MI), Italy; [aleksandra.sojic@itb.cnr.it](mailto:aleksandra.sojic@itb.cnr.it) ; [federica.prinelli@itb.cnr.it](mailto:federica.prinelli@itb.cnr.it);  
30 [fulvio.adorni@itb.cnr.it](mailto:fulvio.adorni@itb.cnr.it);

31

32 \*The authors contributed equally to the manuscript

33

34

35

36

37

38

39

40

41 Corresponding author:

42 Andrea Giacomelli, MD

43 Luigi Sacco DIBIC, University of Milan,

44 III Infectious Diseases Unit, L. Sacco Hospital,

45 Via G.B. Grassi 74,

46 20157 Milano,

47 Italy

48 Tel. +39.02.50319761; Fax +39.02.50319758; E-mail [andrea.giacomelli@unimi.it](mailto:andrea.giacomelli@unimi.it)

49 ORCID ID: 0000-0003-3685-4289

50

51

52

53 **Abstract:** We aimed to assess the reported rate of flu vaccination in the season 2019/2020 in  
54 respondents to the Italian nationwide online EPICOVID 19 survey. A national convenience sample  
55 of volunteers aged 18 or older was assessed between 13<sup>th</sup> April and 2<sup>nd</sup> June 2020. Flu vaccine rates  
56 were calculated for all classes of age. The association between the independent variables and the flu  
57 vaccine was assessed by applying a multivariable binary logistic regression model. Of the 198,822  
58 respondents 41,818 (21.0%) reported to have received a flu vaccination shot during the last  
59 influenza season. In particular, 15,009 (53.4%) subjects aged 65 years or older received a flu  
60 vaccination shot. Being 65 years aged or older (aOR 3.06, 95%CI 2.92-3.20) and having a high  
61 education level (aOR 1.34, 95%CI 1.28-1.41) were independently associated to flu vaccination. Heart  
62 and lung diseases were the morbidities associated with the higher odds of being vaccinated [aOR  
63 1.97 (95%CI 1.86-2.09) and aOR 1.92 (95%CI 1.84-2.01), respectively]. Nursing home residents aged  
64  $\geq$  65 years showed a lower odds of being vaccinated [aOR 0.39 (95%CI 0.28-0.54)]. Our data claims  
65 for an urgent public health effort to fill the gap of missed vaccination opportunities reported in the  
66 past flu seasons.

67

68 **Keywords:** SARS-CoV-2, COVID-19, influenza, vaccine, elderly, Italy

69

70

71

72

73

74

75

## 76 1. Introduction

77 Influenza is an acute viral infection of the respiratory tract, whose clinical manifestations range from  
78 mild upper respiratory tract symptoms to life threatening complications requiring hospitalization. It is  
79 estimated that every year flu can cause worldwide high morbidity and mortality epidemics with  
80 approximately 3 to 5 million cases and between 250,000 and 500,000 deaths [1]. In the northern  
81 hemisphere Influenza viruses circulating during fall and winter seasons cause epidemic outbreaks  
82 with an important burden of morbidity and a remarkable mortality rate. In Italy, the cost for the  
83 national health care system has been estimated an average of 1.4 US\$ billion for each season between  
84 1999 and 2008 [2].

85 The new pandemic caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) has  
86 rapidly spread starting from China in late December 2019 and abruptly involving the north of Italy  
87 in late February 2020 [3]. SARS-CoV-2 infection is able to cause a severe respiratory syndrome with  
88 the requirement of intensive care assistance and eventually leading to death in a significant  
89 percentage of hospitalized patients [4, 5]. The dramatic impact of the SARS-CoV-2 pandemic on the  
90 Italian national healthcare system lead the national authorities to impose a national lock-down from  
91 March 9 to May 18, 2020. After a period of apparent control in summer months, current Italian  
92 epidemiological situation is evolving with a slight daily increment of the number of cases and a  
93 progressive increment of hospitalized patients [6]. Consequently, non-pharmacological  
94 interventions, such as the face mask combined with social distancing, are still enforced.

95 The new challenge in the management of the pandemic will appear in the 2020/2021 flu season,  
96 when the co-occurrence of influenza and flu-like illnesses may overcome the diagnostic capacity of  
97 our system with regard to the capability for molecularly testing all subjects with respiratory  
98 symptoms. Moreover, the clinical impact of subsequent or concomitant influenza and SARS-CoV-2  
99 infections is still unknown, especially in the elderly populations and in patients with comorbidities.

100 To date, no effective treatment has been demonstrated to radically change the natural history of  
101 SARS-CoV-2 infection [7] and several vaccination strategies are still under development [8]; on the  
102 other hand, flu vaccination is able to decrease both the incidence rates of influenza and to moderate  
103 the severity of the disease in case of infection. Moreover, a remarkable decrease in morbidity for  
104 pneumonia, respiratory and cardiovascular complications and consequent risk of hospitalization  
105 and death has been consistently reported in the literature [9-12]. The reduced risk of hospitalization  
106 is particularly important considering the significant amount of hospital resources that are required  
107 for the management of COVID 19 patients which required hospitalization and intensive care  
108 assistance in a not negligible percentage [4, 5]. In the end, influenza vaccinations are not only safe,  
109 with few adverse events related to its administration, but also proven to be effective in children  
110 above 6 months of age, people with comorbid conditions and also in the elderly population [9, 10,  
111 13].

112 Despite national and international recommendations for routine flu vaccination, vaccine uptake in  
113 Italy remains low in the general population, as well as in the high risk groups. Our aim was to  
114 assess the reported rate of flu vaccination in the season 2019/2020 in respondents to the nationwide  
115 online EPICOVID 19 survey [14] and to identify factors associated with the uptake of flu vaccination,  
116 in order to address potential gaps to be filled in the public health system.

## 117 2. Materials and Methods

### 118 2.1 Study design and setting

119 The study design was described elsewhere [14, 15] and the study was registered (ClinicalTrials.gov  
120 NCT04471701). In brief, EPICOVID19 is an Italian cross-sectional, web-based survey that was  
121 initiated in April 2020. A national convenience sample of volunteers aged 18 or older with access to  
122 internet and able to give an informed consent was assessed. The participants were recruited via  
123 social media (Facebook, Twitter, Instagram, Whatsapp), press releases, internet pages, local radio,  
124 TV stations, and institutional websites; the European Commission's open-source official EUSurvey  
125 management tool was used to collect the data (<https://epicovid19.itb.cnr.it/>). The geographical  
126 coverage [14] such as the representativeness of the survey according to the Italian official  
127 demographic data [15] were described elsewhere.

## 128 *2.2 Data collection and variables*

129 For the purposes of this study, we analysed all the survey responses collected between 13<sup>th</sup> April  
130 and 2<sup>nd</sup> June 2020. The socio-demographic information included sex (male vs female, furtherly  
131 classified as pregnant or not), age (18-24, 25-29 up to 90+ and further categorized as <65 or ≥ 65 years  
132 of age), educational level (primary school or less = Low, middle or high school = Medium, and  
133 university degree or post-graduate = High), and occupational status (unemployed, employed,  
134 retired, student, and other). Work categories included in the national guidelines for flu vaccine were  
135 generated (Health professionals, armed forces, agricultural, forestry and fisher workers). Two ad  
136 hoc dummy variables were also created for categorizing residents in nursing homes (yes or not) and  
137 for respondents living with an “at risk cohabitant” according to the 2017-2019 Italian national  
138 vaccination plan (yes or not) [16]. Chronic conditions reported were lung diseases, heart diseases,  
139 metabolic disorders, renal diseases, oncological diseases, diseases of the immune system, liver  
140 diseases and pre-planned major surgical procedures. A new variable was created by summing the  
141 chronic conditions referred by participants (categorised as none, 1, 2 or ≥3 co-morbidities).  
142 Information about autonomy in carrying out daily activities, self-rated health (very bad, bad,  
143 adequate, good or very good) was also available. The participants were also asked if they had  
144 received an influenza vaccination during the previous autumn/winter season.

## 145 *2.3 Study population and group definition*

146 Out of the 207,341 respondents, the study population consisted of 198,822 participants who provided  
147 informed consent, and for whom the data were fully available for the analysis. For the aim of this  
148 study, participants were categorized as vaccinated or not vaccinated for flu during the 2019/2020  
149 season.

## 150 *2.4 Statistical analysis*

151 Descriptive analyses were performed to show the numerical distributions, overall and by flu vaccine  
152 status, of all the variables that at a later stage were included as independent in the models applied  
153 for statistical inference. Continuous variables were expressed as mean [Standard Deviation (SD)]  
154 whereas categorical and ordinal ones as count and percentages. Flu vaccine rates were calculated for  
155 all classes of age and for all Italian regions, in this latter case also stratifying by sex (male vs female)  
156 and age (<65 vs ≥65 years). The association between the independent variables and the flu vaccine  
157 (0=not reported, 1=reported) was assessed by applying a multivariable binary logistic regression  
158 model. Adjusted Odds Ratios (aOR), together with their 95% Confidence Intervals (CI), were  
159 estimated for each independent variable, with p-level of statistical significance set at .05, two tails.  
160 The same regression model was used when restricting the population analysed to older people (≥65  
161 years). All the statistical analyses were carried out using SPSS version 25 (IBM Corp) and STATA  
162 version 15.0 (StataCorp LP).

## 163 *2.5 Ethics and consent to participate*

164 The Ethics Committee of the National Institute for Infectious Diseases (Italian: Istituto Nazionale per  
 165 le Malattie Infettive I.R.C.C.S. Lazzaro Spallanzani) approved the EPICOV19 study protocol  
 166 (Protocol No. 70, 12/4/2020). The participants were requested to give their informed consent when  
 167 they first accessed the on-line platform. The study was carried out in accordance with the principles  
 168 of the Declaration of Helsinki.

169 All data were handled and stored in accordance with the European Union General Data Protection  
 170 Regulation (EU GDPR) 2016/679; data transfer included encrypting/decrypting and password  
 171 protection.

### 172 3. Results

173 Between April and June 2020 198,822 participants filled the online EPICOV19 survey and 41,818  
 174 (21.0%) reported to have received a flu vaccination shot during the last influenza season (2019/2020).  
 175 Respondents were prevalently females (59.7%) and aged between 18-64 years (85.9%) with a mean  
 176 age of 48 (SD +/- 14.7 years) (Table 1).

177

		Flu shot during 2019/2020 flu season		
		No	Yes	Total
		N=157004	N=41818 (21.0)	N=198822
		(79.0)		(100)
Sex at birth	Females	95402 (80.4)	23255 (19.6)	118657 (59.7)
	Males	61602 (76.8)	18563 (23.2)	80165 (40.3)
Class of age	<65 years	143921 (84.3)	26809 (15.7)	170730 (85.9)
	65+ years	13083 (46.6)	15009 (53.4)	28092 (14.1)
Age		45.9 ± 13.6	55.8 ± 15.9	48.0 ± 14.7
Educational level	Low	8662 (73.1)	3192 (26.9)	11854 (6.0)
	Middle	56058 (81.5)	12742 (18.5)	68800 (34.6)
	High	92284 (78.1)	25884 (21.9)	118168 (59.4)
Employment status	Employed	114488 (83.7)	22368 (16.3)	136856 (68.8)
	Student	11781 (87.7)	1655 (12.3)	13436 (6.8)
	Unemployed	8064 (87.8)	1120 (12.2)	9184 (4.6)
	Retired	14056 (49.7)	14252 (50.3)	28308 (14.2)
	Other	8615 (78.0)	2423 (22.0)	11038 (5.6)
Morbidities or clinical conditions	Lung diseases	7497 (65.4)	3959 (34.6)	11456 (5.8)
	Heart disease	2996 (47.5)	3318 (52.5)	6314 (3.2)
	Metabolic disorders	5662 (60.7)	3663 (39.3)	9325 (4.7)
	Renal diseases	1044 (61.8)	644 (38.2)	1688 (0.8)
	Oncological diseases	3809 (60.0)	2541 (40.0)	6350 (3.2)
	Diseases of the immune system	12998 (74.2)	4516 (25.8)	17514 (8.8)
	Liver diseases	999 (67.2)	488 (32.8)	1487 (0.7)
	Surgical procedures	5499 (72.3)	2103 (27.7)	7602 (3.8)
Number of morbidities	None	123240 (82.6)	25928 (17.4)	149168 (75.0)
	One	28077 (70.6)	11689 (29.4)	39766 (20.0)
	Two	4782 (59.2)	3297 (40.8)	8079 (4.1)

	Three or more	905 (50.0)	904 (50.0)	1809 (0.9)
Work categories recommended for flu vaccine	Health professionals	9474 (64.3)	5262 (35.7)	14736 (7.4)
	Armed forces	1610 (79.8)	407 (20.2)	2017 (1.0)
	Agricultural, forestry and fishery workers	674 (82.3)	145 (17.7)	819 (0.4)
Other conditions for recommending flu vaccine	Pregnancy	2446 (76.7)	743 (23.3)	3189 (1.6)
	Residents in nursing home	129 (39.0)	202 (61.0)	331 (0.2)
	Cohabitants at risk	26883 (70.5)	11225 (29.5)	38108 (19.2)
Self-perceived health status	Not self-sufficient in carrying out daily activities	425 (46.0)	499 (54.0)	924 (0.5)
	Good	135325 (80.9)	31942 (19.1)	167267 (84.1)
	Adequate	20585 (69.2)	9159 (30.8)	29744 (15.0)
	Bad	1094 (60.4)	717 (39.6)	1811 (0.9)

178 Table 1: characteristics of study participants according to being or not vaccinated for  
179 influenza in the 2019/2020 flu season.

180

181 Vaccination coverage progressively increased with age, from 11% between 18 and 24 years of age  
182 and peaking to 72.9% between 85 and 89 years of age (Supplementary Table 1).

Class of age	Flu shot during 2019/2020 flu season		
	No N=157004 (79.0)	Yes N=41818 (21.0)	Total N=198822 (100)
18-24	8916 (89.0)	1099 (11.0)	10015 (5.0)
25-29	12965 (87.6)	1839 (12.4)	14804 (7.4)
30-34	15539 (87.1)	2311 (12.9)	17850 (9.0)
35-39	17049 (85.6)	2864 (14.4)	19913 (10.0)
40-44	17260 (85.0)	3036 (15.0)	20296 (10.2)
45-49	19391 (86.4)	3055 (13.6)	22446 (11.3)
50-54	19848 (86.0)	3235 (14.0)	23083 (11.6)
55-59	18753 (81.7)	4195 (18.3)	22948 (11.5)
60-64	14200 (73.3)	5175 (26.7)	19375 (9.7)
65-69	7885 (55.3)	6373 (44.7)	14258 (7.2)
70-74	3504 (41.1)	5018 (58.9)	8522 (4.3)
75-79	1081 (35.1)	2003 (64.9)	3084 (1.6)
80-84	379 (27.5)	998 (72.5)	1377 (0.7)
85-89	136 (27.0)	367 (73.0)	503 (0.3)
90+	98 (28.2)	250 (71.8)	348 (0.2)

183 Supplementary Table 1. Vaccination coverage in participants according to the class of age.

184


185 In particular, 15,009 (53.4%) subjects aged 65 years or older received a flu vaccination shot during the  
 186 last influenza season. The comparison between vaccination covered per class of age and the official  
 187 Italian from are reported in Supplementary Table 2.

		Flu shot rates by class of age	
		National 2109-2020	EPICOVID19
Class of age	18-44 years	574,335/18,526,934 (3.1)	11,149/82,878 (13.5)
	45-64 years	1,749,887/18,227,994 (9.6)	15,660/87,852 (17.8)
	18-64 years	2,324,222/36,754,928 (6.3)	26,809/170,730 (15.7)
	65+ years	7,615,037/13,946,954 (54.6)	15,009/28,092 (53.4)
	60-64 years	-	5,175/19,375 (26.7)

188 Supplementary Table 2. Vaccination coverage per class of age according to the Italian  
 189 official national data and in the EPICOVID19 respondents.

190 More than half of the respondents (59.4%) had high educational level, whereas 34.6% and 6%  
 191 reported medium and high educational level. More than seventy-five percent of respondents  
 192 (149,168; 75%) reported no diseases, whereas the remaining 25% reported at least one clinical  
 193 condition representing *per se* a flu vaccine indication. Vaccination coverage progressively increased  
 194 up to 50.0% in those reporting 3 or more comorbidities. Among participants reporting at least one  
 195 condition, those with heart disease showed the higher vaccination coverage (52.5%) followed by  
 196 those reporting oncological diseases (40%) and metabolic disorders (39%); whereas only 34.6% of  
 197 those with lung diseases reported to be vaccinated for influenza. Among the professions with an  
 198 indication for flu vaccination, health care workers were those with the higher coverage (35.7%).

199 Vaccination coverage ranged widely across Italian regions, from 18.2% in Abruzzo to 23.7% in  
 200 Friuli-Venezia Giulia in the overall respondents (Figure 1A) and from 48.7% in Piemonte to 63.6%  
 201 Friuli-Venezia Giulia in those aged  $\geq 65$  years (Figure 1B).




203 Figure 1. A, vaccination coverage according to the different Italian region in respondents  
 204 aged  $\geq 18$  years. B, vaccination coverage according to the different Italian regions in  
 205 respondents aged  $\geq 65$  years.

206

207 **3.1 Multivariable model of factors associated to flu vaccination**

208 Figure 2 shows the multivariable model for subjects aged 18 years or older.



209

210 Figure 2. Multivariable model of factors associated to flu vaccination in the 2019/2020  
 211 season in respondents aged  $\geq 18$  years.

212 The multivariable model stratified by age (18-64 years and  $\geq 65$  years) are reported in Table 2. When  
 213 considering the whole respondents, being 65 years or older (aOR 3.06, 95%CI 2.92-3.20) and having a  
 214 high education level (aOR 1.34, 95%CI 1.28-1.41) were independently associated to flu vaccination.  
 215 Conversely, those unemployed showed a reduced odds of being vaccinated (aOR 0.80, 95%CI  
 216 0.75-0.85).

217

218

219

220

221

222

223

224

225

226

227

	Age 18-64 years		Age ≥ 65 years	
	N=26.809/170.730 (15.7)		N=15.009/28.092	
	aOR (95%CI)	p	aOR (95%CI)	p
Sex and pregnancy				
Males	1		1	
Not pregnant females	0.83 (0.81 to 0.85)	.000	1.19 (1.13 to 1.25)	.000
Pregnant females	1.68 (1.54 to 1.85)	.000		
Age, per 10 years more	1.24 (1.22 to 1.26)	.000	2.01 (1.90 to 2.12)	.000
Educational level				
Low	1		1	
Middle	1.08 (1.01 to 1.16)	.034	1.06 (0.98 to 1.14)	.134
High	1.59 (1.49 to 1.71)	.000	1.40 (1.29 to 1.52)	.000
Employment status				
Employed	1		1	
Student	1.50 (1.40 to 1.59)	.000	-	
Unemployed	0.88 (0.82 to 0.94)	.000	1.11 (0.80 to 1.53)	.532
Retired	1.65 (1.54 to 1.76)	.000	1.52 (1.40 to 1.64)	.000
Other	1.09 (1.02 to 1.15)	.006	1.24 (1.10 to 1.40)	.001
Morbidities or clinical conditions				
Lung diseases	1.95 (1.85 to 2.05)	.000	1.91 (1.73 to 2.10)	.000
Heart disease	2.15 (1.98 to 2.33)	.000	1.54 (1.42 to 1.66)	.000
Metabolic disorders	1.68 (1.58 to 1.78)	.000	1.33 (1.23 to 1.44)	.000
Renal diseases	1.41 (1.22 to 1.63)	.000	1.10 (0.91 to 1.30)	.305
Oncological diseases	1.62 (1.50 to 1.75)	.000	1.16 (1.06 to 1.26)	.001
Diseases of the immune system	1.17 (1.12 to 1.23)	.000	1.02 (0.94 to 1.10)	.583
Liver diseases	1.00 (0.85 to 1.18)	.972	0.92 (0.76 to 1.10)	.410
Surgical procedures	1.06 (0.99 to 1.14)	.093	1.13 (1.02 to 1.24)	.021
Work categories recommended for flu vaccine				
Not recommended	1		1	
Agricultural, forestry and fishery workers	0.79 (0.62 to 1.00)	.047	0.97 (0.66 to 1.41)	.895
Armed forces	0.97 (0.85 to 1.12)	.699	1.24 (0.93 to 1.66)	.139
Health professionals	2.99 (2.87 to 3.11)	.000	1.54 (1.36 to 1.73)	.000
Other conditions for recommending flu vaccine				
Residents in nursing home	7.20 (4.29 to 12.10)	.000	0.39 (0.28 to 0.54)	.000
Presence of persons at risk in the household	1.36 (1.31 to 1.40)	.000	1.42 (1.35 to 1.49)	.000
Not self-sufficient in carrying out daily activities	1.83 (1.41 to 2.38)	.000	0.54 (0.43 to 0.67)	.000
Self-perceived health status				
Good	1		1	
Adequate	1.15 (1.10 to 1.19)	.000	1.16 (1.10 to 1.22)	.000

Bad 1.24 (1.08 to 1.42) .002 1.36 (1.12 to 1.62) .002

228 Table 2. Multivariable binary logistic regression analysis on the probability of being or not  
 229 vaccinated during the 2019/2020 flu season according to being 18-64 years old or ≥ 65 years  
 230 old.

231 Among comorbidities, heart and lung diseases were conditions associated with higher odds of being  
 232 vaccinated, both in subjects aged 18-64 [aOR 2.15 (1.98 to 2.33) and aOR 1.95 (1.85 to 2.05),  
 233 respectively] and in those aged above 65 years [aOR 1.54 (95%CI 1.42-1.67) and aOR 1.91 (95%CI  
 234 1.73-2.12), respectively]. The odds of being vaccinated progressively increased with the number of  
 235 reported morbidities, with a more pronounced effect in those aged below 65 years (Supplementary  
 236 Table 3).

	Age 18-64 years		Age ≥ 65 years	
	N=26.809/170.730 (15.7)		N=15.009/28.092 (53.4)	
	aOR (95%CI)	p	aOR (95%CI)	p
Number of morbidities				
None	1		1	
One	1.54 (1.49 to 1.59)	.000	1.43 (1.35 to 1.51)	.000
Two	2.18 (2.05 to 2.33)	.000	1.70 (1.55 to 1.86)	.000
Three or more	2.60 (2.26 to 2.99)	.000	1.66 (1.42 to 1.94)	.000

237 Supplementary Table 3. Multivariable binary logistic regression analysis on the probability  
 238 of being or not vaccinated during the 2019/2020 flu season according to the number of  
 239 reported morbidities.

240 Health care workers showed a higher odds of being vaccinated [aOR 2.79 (95%CI 2.68-2.90)] when  
 241 compared to work position without vaccine recommendation.

242 Living in a nursing home and being unable to perform daily activities were both associated with a  
 243 lower odds of being vaccinated in those aged 65 years or older [aOR 0.39 (95%CI 0.28-0.54) and aOR  
 244 0.54 (95%CI 0.43-0.69), respectively].

#### 245 4. Discussion

246 The EPICOVID 19 web based survey, which aimed to highlight different epidemiological and  
 247 clinical aspects of COVID-19 epidemic in the first wave of the Italian epidemic, allowed the  
 248 assessment of flu vaccination coverage in the 2019/2020 flu season in a large unselected sample of  
 249 respondents. Moreover, we were able to identify predictors of flu vaccine uptake and highlight  
 250 significant gaps in vaccination coverage in key populations such as in those residing in nursing  
 251 homes and in those reporting specific medical conditions (i.e. liver diseases, kidney diseases and  
 252 diseases of the immune system).

253 Our findings showed an overall vaccination rate of 21% and a rate of 53.4% in those aged 65 years or  
 254 older, clearly below the target recommended coverage. The available National data obtained from a  
 255 surveillance system collecting data from the general practitioners since 1990/2000 flu season, report a  
 256 progressive increase in the vaccination coverage until 2009/2010 for the overall population (19.6 per  
 257 100 inhabitants) and until 2008/2009 for those aged 65 years or older (66.3 per 100 inhabitants). A  
 258 progressive decline was subsequently observed for those aged 65 years or older until 2014/2015 (48.5  
 259 per 100 inhabitants) followed by a slight progressive increase in the subsequent years [17].  
 260 According to the official data of the Italian Ministry of Health of vaccination coverage in 2019/2020  
 261 flu season the overall vaccination coverage in the whole Italian population was 16.7 over 100  
 262 inhabitants and 54.6 over 100 inhabitants in those aged 65 years or older confirming the trend

263 toward an increasing vaccination coverage [18]. Our data can not to be applied to the general  
264 estimates due to the absence in the survey of subjects aged 17 or younger. Whereas, the vaccination  
265 coverage observed in those aged 65 years or older appeared to be quite comparable to that reported  
266 by the official estimates (53.4% vs 54.6%, respectively). Although slightly increasing in recent years,  
267 the percentage observed in our study is lower than the target coverage of 75% in those aged 65 years  
268 or older. These data are particularly worrisome, because in the current fall/winter season in the  
269 northern hemisphere, with the concomitant co-circulation of both influenza and SARS-CoV-2  
270 viruses, we will face a major challenge due to diagnostic and clinical problems in the presence of  
271 upper and lower respiratory tract symptoms [19]. Based on these concerns, for the 2020/2021 flu  
272 season the Italian ministry of Health recommends extending the vaccination coverage to the whole  
273 population, free of charge also for subject aged between 60 and 64 years [20]. If the free-of-charge  
274 administration of the influenza vaccine in this age-group will improve the uptake is to be  
275 demonstrated, but it will help to quantify the impact of the economical barrier to vaccination.

276 Recent findings support the need to increase the vaccination coverage, considering, on top of the  
277 well-known health and economic advantages, also the observed association between flu vaccination  
278 and reduction in SARS-CoV-2 nasopharyngeal swab positivity [15] and lower COVID-19 severity  
279 and mortality [21-23]. Therefore, the impact of vaccinations should be assessed not only based on  
280 their ability to prevent the related infections, but also on their broader impact on other  
281 communicable and not-communicable diseases occurring concurrently in the target population.

282 Our findings highlight a worrisome low vaccination coverage in subjects aged between 60-64 years  
283 and 65-69 years (26.7% and 44.7%, respectively). The low vaccination coverage in this group could be  
284 partially explained by a self-perception of wellbeing and low risk perception [24]. Nevertheless,  
285 these age groups are at high risk of COVID-19 complications and mortality, as observed in the Italian  
286 COVID-19 patients, therefore strategies to overcome their hesitancy towards vaccines and to  
287 increase vaccine accessibility and uptake are of paramount relevance [4, 25].

288 Another interesting finding observed is that people with higher education level seems to be better  
289 predisposed to vaccination when compared to the low socio-economic level. If on the one hand, low  
290 education level is a known general barrier to vaccines [26] on the other, our sample of generally  
291 higher educational level compared to the general population, reported overall a low uptake,  
292 meaning that multiple factors, beyond health literacy and access to health care services, need to be  
293 addressed. Moreover, the finding of a higher coverage among those with comorbidities suggest an  
294 attitude to consider the vaccination as a relevant intervention mainly for individuals at high risk,  
295 and not as a meaningful intervention for health promotion [27].

296 Our results showed that patients with heart and lung diseases seem to have a higher odds of being  
297 vaccinated when compared to those with other comorbidities, in particular kidney and liver disease.  
298 These findings raise particular concern, because it is clearly demonstrated that patients with chronic  
299 conditions, not only cardiovascular or respiratory diseases, are at higher risk of many  
300 vaccine-preventable diseases, including influenza, that increase the risk of serious complications,  
301 hospitalization, and death. Moreover, vaccine preventable diseases are more difficult to manage,  
302 because of increased risk of drug interactions and potential adverse effects [27].

303 In our study, flu vaccination resulted positively associated with being a health care worker,  
304 compared to other work-categories. Nevertheless, an extremely low percentage of health care  
305 workers respondents accounting for 35.7% received a flu shot in the last season. Although the  
306 percentage reported in our study is surprisingly higher compared to that reported in the literature in  
307 Italian health care workers, ranging from 14% [28] to 16% [29], it underlines the need for urgent  
308 measures to increase vaccination coverage in Italian health care workers. Vaccination of health care  
309 workers against influenza is a key component of infection control, and the rationale for it is based on  
310 the need to protect the health care workers and their high-risk patients in nursing homes, hospitals,

311 and outpatient clinics. Moreover, in time of extreme demand, reducing the absenteeism due to  
312 influenza and its complications, contributes to the preservation of the essential health care services.

313 The finding that nursing home residents aged 65 years or older have a 61% higher odds of not being  
314 vaccinated compared to the rest of the population was unexpected and definitively worrisome.  
315 These subjects have high rates of underlying medical conditions and, therefore, are at higher risk of  
316 infectious disease outbreaks. As we have learned during the recent pandemic, about half of deaths  
317 due to COVID-19 were among nursing homes residents, underlying a critical health disparity that  
318 need to be addressed urgently. Increased vaccination rates and increased testing for preventable  
319 infectious disease of residents and staff, and increased access to personal protective measures and  
320 equipment are mandatory in all nursing homes, in order to protect this vulnerable subgroup of our  
321 population [30-32].

#### 322 *4.1 Strengths and limitations*

323 The main strength of our research was the possibility to assess factors associated with flu vaccination  
324 in a large unselected group of respondents to an online survey. In fact, Italian estimates on past flu  
325 vaccination seasons reported aggregated data for the general population and for those aged 65 years  
326 or older but failed to address among the target group which are categories with significant barriers  
327 to achieve the pre-planned goal for flu vaccine coverage.

328 Our study has several limitations. First, the absence of subjects aged below 18 years makes  
329 impossible the comparison of our data with that of the Italian general population reported by the  
330 ministry of health. Second, the high percentage of high education and health care workers observed  
331 in our sample should be considered in the interpretation of the results for the possible impact on  
332 behaviours and opportunities toward a better health. Third, caution is warranted in the  
333 interpretation of flu vaccination coverage of nursing home residents due to the possibility of  
334 recalling bias. In the end, the sample cannot be considered fully representative of the Italian  
335 demographic curve and consequently our findings could be not completely generalizable to the  
336 Italian population.

#### 337 **5. Conclusions**

338 Our data confirm a low vaccination coverage in the overall respondents to the online EPICOVID 19  
339 survey and in particular, far below the national recommendations in target populations, such as  
340 those 65 years or older, in subjects at high risk due to chronic conditions and in health care workers.  
341 In the perspective of the next fall winter season, with the probable co-circulation of influenza and  
342 SARS-CoV-2 in the norther hemisphere, the population will remain vulnerable to concurrent  
343 epidemics. The morbidity and mortality impact will be directly related to the strength of the public  
344 health response, which must be based on effective infection prevention tools currently available: the  
345 non-pharmacologic interventions (i.e. social distance and face masks) and the widespread  
346 implementation of influenza vaccination to fill the gap of missed vaccination opportunities reported  
347 in the past flu seasons.

348 **Supplementary Materials:** The following are available online at [www.mdpi.com/xxx/s1](http://www.mdpi.com/xxx/s1),

349 Supplementary Table 1. Vaccination coverage in participants according to the class of age.

350 Supplementary Table 2. Vaccination coverage per class of age according to the Italian official national data for  
351 the 2019/2020 flu season and in the EPICOVID19 respondents.

352 Supplementary Table 3. Multivariable binary logistic regression analysis on the probability of being or not  
353 vaccinated during the 2019/2020 flu season according to the number of reported morbidities.

354 **Author Contributions:** Conceptualization, A.G., M.G., S.M., F.P., F.A.; Formal analysis, F.P., F.A.; Methodology,  
355 A.G., M.G., S.M., F.P. and F.A.; Project administration, F.A.; Supervision, M.G. and F.A.; Writing—original draft,  
356 A.G., M.G., F.P., S.M. and F.A.; Writing—review & editing, S.M., M.N., C.T., R. A.I, G.P., G.B, M.D.B, A.S., M.T.,  
357 C.M., M.A., F.P., F.A. The corresponding author, A.G., attests that all listed authors meet authorship criteria and  
358 that no others meeting the criteria have been omitted. All authors have read and agreed to the published  
359 version of the manuscript.

360 **Funding:** This research received no external funding

361 **Acknowledgments:** The EPICOV19 Working Group: Fulvio Adorni (National Research Council, Institute of  
362 Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy); Federica Prinelli (National Research  
363 Council, Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy); Fabrizio Bianchi  
364 (National Research Council, Institute of Clinical Physiology, Via G. Moruzzi 1, 56124 Pisa (PI), Italy); Andrea  
365 Giacomelli (Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di  
366 Milano, ASST Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy); Gabriele Pagni  
367 (Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di Milano, ASST  
368 Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy); Dario Bernacchia (Infectious  
369 Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di Milano, ASST  
370 Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy); Stefano Rusconi (Infectious Diseases  
371 Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di Milano, ASST Fatebenefratelli  
372 Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy); Stefania Maggi (National Research Council,  
373 Neuroscience Institute, Aging branch, Via Vincenzo Maria Gallucci 16, 35128 Padova, Italy); Caterina Trevisan  
374 (University of Padova, Department of Medicine (DIMED) – Geriatric Unit, Via Giustiniani 2, 35128 Padova  
375 (PD), Italy); National Research Council, Neuroscience Institute, Via Giustiniani 2, 35128 Padova (PD), Italy);  
376 Marianna Noale (National Research Council, Neuroscience Institute, Aging branch, Via Vincenzo Maria  
377 Gallucci 16, 35128 Padova, Italy); Sabrina Molinaro (National Research Council, Institute of Clinical Physiology,  
378 Via G. Moruzzi 1, 56124 Pisa (PI), Italy); Luca Bastiani (National Research Council, Institute of Clinical  
379 Physiology, Via G. Moruzzi 1, 56124 Pisa (PI), Italy); Loredana Fortunato (National Research Council, Institute  
380 of Clinical Physiology, Via G. Moruzzi 1, 56124 Pisa (PI), Italy); Nithiya Jesuthasan (National Research Council,  
381 Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy); Aleksandra Sojic (National  
382 Research Council, Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy); Carla  
383 Pettenati (National Research Council, Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate  
384 (MI), Italy); Marcello Tavio (Division of Infectious Diseases, Azienda Ospedaliero Universitaria Ospedali  
385 Riuniti, Ancona, Italy); Massimo Andreoni (Infectious Diseases Clinic, Department of System Medicine, Tor  
386 Vergata University of Rome, 00133 Rome, Italy); Claudio Mastroianni (Public Health and Infectious Disease  
387 Department, "Sapienza" University, Rome, Italy); Raffaele Antonelli Incalzi (Unit of Geriatrics, Department of  
388 Medicine, Biomedical Campus of Rome, via Alvaro del Portillo, 21, 00128 Rome, Italy); Massimo Galli  
389 (Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di Milano, ASST  
390 Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy).


391 **Conflicts of Interest:** The authors declare no conflict of interest.

## 392 References

- 393 1. [http://www.who.int/influenza/gisrs\\_laboratory/en/](http://www.who.int/influenza/gisrs_laboratory/en/) accessed 23/09/2020
- 394 2. Lai PL, Panatto D, Ansaldi F et al. Burden of the 1999-2008 seasonal influenza epidemics in Italy:  
395 comparison with the H1N1v (A/California/07/09) pandemic. *Hum Vaccin.* 2011 Jan-Feb;7 Suppl:217-25.
- 396 3. Zehender G, Lai A, Bergna A, et al. Genomic characterization and phylogenetic analysis of SARS-COV-2 in  
397 Italy [published online ahead of print, 2020 Mar 29]. *J Med Virol.* 2020;10.1002/jmv.25794.
- 398 4. Giacomelli A, Ridolfo AL, Milazzo L, et al. 30-day mortality in patients hospitalized with COVID-19  
399 during the first wave of the Italian epidemic: A prospective cohort study. *Pharmacol Res.* 2020;158:104931.
- 400 5. Grasselli G, Zangrillo A, Zanella A, et al; COVID-19 Lombardy ICU Network. Baseline Characteristics and  
401 Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.  
402 *JAMA.* 2020 Apr 28;323(16):1574-1581.


- 403 6. <https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-dashboard> accessed 23/09/2020
- 404 7. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and  
405 network meta-analysis. *BMJ*. 2020;370:m2980. Published 2020 Jul 30. doi:10.1136/bmj.m2980
- 406 8. Bar-Zeev N, Inglesby T. COVID-19 vaccines: early success and remaining challenges. *Lancet*. 2020 Sep  
407 3:S0140-6736(20)31867-5. doi: 10.1016/S0140-6736(20)31867-5.
- 408 9. Demicheli V, Jefferson T, Di Pietrantonj C, et al. Vaccines for preventing influenza in the elderly. *Cochrane*  
409 *Database Syst Rev*. 2018;2(2):CD004876.
- 410 10. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy  
411 children. *Cochrane Database Syst Rev*. 2018;2(2):CD004879. Published 2018 Feb 1.  
412 doi:10.1002/14651858.CD004879.pub5
- 413 11. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in  
414 healthy adults. *Cochrane Database Syst Rev*. 2018;2(2):CD001269.
- 415 12. Demurtas J, Celotto S, Beaudart C, et al. The efficacy and safety of influenza vaccination in older people:  
416 An umbrella review of evidence from meta-analyses of both observational and randomized controlled  
417 studies. *Ageing Res Rev*. 2020;62:101118.
- 418 13. Bonanni P, Boccalini S, Zanobini P, et al. The appropriateness of the use of influenza vaccines:  
419 Recommendations from the latest seasons in Italy. *Hum Vaccin Immunother*. 2018 Mar 4;14(3):699-705.
- 420 14. Adorni F, Prinelli F, Bianchi F, et al. Self-reported symptoms of SARS-CoV-2 infection in a  
421 non-hospitalized population: results from the large Italian web-based EPICOV19 cross-sectional survey  
422 [published online ahead of print, 2020 Jul 10]. *JMIR Public Health Surveill*. 2020;10.2196/21866.
- 423 15. Noale M, Trevisan C, Maggi S, et al. The Association between Influenza and Pneumococcal Vaccinations  
424 and SARS-Cov-2 Infection: Data from the EPICOV19 Web-Based Survey. *Vaccines (Basel)*.  
425 2020;8(3):E471.
- 426 16. [http://www.salute.gov.it/imgs/C\\_17\\_pubblicazioni\\_2571\\_allegato.pdf](http://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf) accessed 23/09/2020
- 427 17. [http://www.salute.gov.it/portale/influenza/dettaglioContenutiInfluenza.jsp?lingua=italiano&id=679&area](http://www.salute.gov.it/portale/influenza/dettaglioContenutiInfluenza.jsp?lingua=italiano&id=679&area=influenza&menu=vuoto)  
428 [=influenza&menu=vuoto](http://www.salute.gov.it/portale/influenza/dettaglioContenutiInfluenza.jsp?lingua=italiano&id=679&area=influenza&menu=vuoto) accessed 23/09/2020
- 429 18. [https://www.epicentro.iss.it/vaccini/dati\\_Ita#flu](https://www.epicentro.iss.it/vaccini/dati_Ita#flu) accessed 23/09/2020
- 430 19. Solomon DA, Sherman AC, Kanjilal S. Influenza in the COVID-19 Era. *JAMA*. Published online August 14,  
431 2020. doi:10.1001/jama.2020.14661
- 432 20. [https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2020&codLeg=74451&parte=1%20](https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2020&codLeg=74451&parte=1%20&serie=null)  
433 [0&serie=null](https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2020&codLeg=74451&parte=1%20&serie=null) Accessed 23/9/2020
- 434 21. Zanettini C, Omar M, Dinalankara W, et al. Influenza Vaccination and COVID19 Mortality in the USA.  
435 Preprint. *medRxiv*. 2020;2020.06.24.20129817. Published 2020 Jun 26. doi:10.1101/2020.06.24.20129817
- 436 22. Fink, G.; Orlova-Fink, N.; Schindler, T.; Grisi, S.; Ferrer, A.P.; Daubenberger, C.; Brentani, A. Inactivated  
437 trivalent influenza vaccine is associated with lower mortality among Covid-19 patients in  
438 Brazil. *medRxiv* 2020.06.29.20142505; doi: <https://doi.org/10.1101/2020.06.29.20142505>
- 439 23. Amato M, Werba JP, Frigerio B, et al. Relationship between Influenza Vaccination Coverage Rate and  
440 COVID-19 Outbreak: An Italian Ecological Study. *Vaccines (Basel)*. 2020;8(3):E535.

- 441 24. Schmid P, Rauber D, Betsch C, Lidolt G, Denker ML. Barriers of Influenza Vaccination Intention and  
442 Behavior - A Systematic Review of Influenza Vaccine Hesitancy, 2005 - 2016. *PLoS One*.  
443 2017;12(1):e0170550. Published 2017 Jan 26. doi:10.1371/journal.pone.0170550
- 444 25. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to  
445 COVID-19 in Italy. *JAMA*. 2020;323(18):1775–1776. doi:10.1001/jama.2020.4683
- 446 26. Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Understanding vaccine hesitancy around  
447 vaccines and vaccination from a global perspective: a systematic review of published literature,  
448 2007-2012. *Vaccine*. 2014;32(19):2150-2159.
- 449 27. Doherty TM, Del Giudice G, Maggi S. Adult vaccination as part of a healthy lifestyle: moving from  
450 medical intervention to health promotion. *Ann Med*. 2019;51(2):128-140.
- 451 28. Genovese C, Picerno IAM, Trimarchi G, et al. Vaccination coverage in healthcare workers: a multicenter  
452 cross-sectional study in Italy. *J Prev Med Hyg*. 2019;60(1):E12-E17.
- 453 29. Alicino C, Iudici R, Barberis I, et al. Influenza vaccination among healthcare workers in  
454 Italy. *Hum Vaccin Immunother* 2015;11(1):95-100.
- 455 30. Abrams HR, Loomer L, Gandhi A, Grabowski DC. Characteristics of U.S. Nursing Homes with COVID-19  
456 Cases. *J Am Geriatr Soc*. 2020 Aug;68(8):1653-1656.
- 457 31. Roxby AC, Greninger AL, Hatfield KM, et al. Outbreak Investigation of COVID-19 Among Residents and  
458 Staff of an Independent and Assisted Living Community for Older Adults in Seattle, Washington. *JAMA*  
459 *Intern Med*. 2020;180(8):1101-1105.
- 460 32. Nanda A, Vura NVRK, Gravenstein S. COVID-19 in older adults. *Aging Clin Exp Res*. 2020  
461 Jul;32(7):1199-1202. doi: 10.1007/s40520-020-01581-5. Epub 2020 May 10. PMID: 32390064; PMCID:  
462 PMC7211267
- 463




medRxiv preprint doi: <https://doi.org/10.1101/2020.09.30.20202020>; this version posted September 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

# A



# B



medRxiv preprint doi: <https://doi.org/10.1101/2020.09.30.20244902>; this version posted September 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.